-->

Tag: Nectin-4 PD-1 dual targeting

Home / Nectin-4 PD-1 dual targeting

Categories

Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial cancer

As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advan...
nectin-4-pd-1-dual-targeting

Scan the code